Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475490 | 0.78 | CA2 (0.34) | NLRP3 | |
| SCHEMBL21892985 | 0.75 | NLRP3 (0.34) | NLRP3 | |
| SCHEMBL22012140 | 0.73 | NLRP3 (0.32) | NLRP3 | |
| SCHEMBL20681411 | 0.70 | — | — | |
| SCHEMBL22014915 | 0.69 | CYP3A4 (0.33) | ALDH1A1NPC1NLRP3POLBLMNA | |
| SCHEMBL22002754 | 0.68 | NLRP3 (0.32) | NLRP3 | |
| SCHEMBL28316717 | 0.67 | HCRTR2 (0.33) | ALDH1A1NPC1NLRP3POLBLMNA | |
| SCHEMBL20914749 | 0.65 | ALDH1A1 (0.37) | ALDH1A1NPC1 | |
| SCHEMBL3605034 | 0.64 | SMN1; SMN2 (0.46) | ALDH1A1NPC1POLBLMNA | |
| SCHEMBL25139085 | 0.64 | HTR1A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 2176/4885NPC1 51/4885NLRP3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.